Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Niels Grote Beverborg
 -- 4895 2022-04-11 10:54:26 |
2 format done
Vicky Zhou
 + 2 word(s) 4897 2022-04-11 11:37:31 | |
3 format done
Vicky Zhou
 -35 word(s) 4862 2022-04-11 11:53:26 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Grote Beverborg, N.; , .; Van Der Meer, P. Iron Deficiency in Heart Failure. Encyclopedia. Available online: https://encyclopedia.pub/entry/21562 (accessed on 27 July 2024).
Grote Beverborg N,  , Van Der Meer P. Iron Deficiency in Heart Failure. Encyclopedia. Available at: https://encyclopedia.pub/entry/21562. Accessed July 27, 2024.
Grote Beverborg, Niels, , Peter Van Der Meer. "Iron Deficiency in Heart Failure" Encyclopedia, https://encyclopedia.pub/entry/21562 (accessed July 27, 2024).
Grote Beverborg, N., , ., & Van Der Meer, P. (2022, April 11). Iron Deficiency in Heart Failure. In Encyclopedia. https://encyclopedia.pub/entry/21562
Grote Beverborg, Niels, et al. "Iron Deficiency in Heart Failure." Encyclopedia. Web. 11 April, 2022.
Iron Deficiency in Heart Failure
Edit
This entry is adapted from the peer-reviewed paper 10.3390/jcm11010125

Iron is an essential micronutrient for a myriad of physiological processes in the body beyond erythropoiesis. Iron deficiency (ID) is a common comorbidity in patients with heart failure (HF), with a prevalence reaching up to 59% even in non-anaemic patients. ID impairs exercise capacity, reduces the quality of life, increases hospitalisation rate and mortality risk regardless of anaemia. Intravenously correcting ID has emerged as a promising treatment in HF as it has been shown to alleviate symptoms, improve quality of life and exercise capacity and reduce hospitalisations. However, the pathophysiology of ID in HF remains poorly characterised. Recognition of ID in HF triggered more research with the aim to explain how correcting ID improves HF status as well as the underlying causes of ID in the first place. In the past few years, significant progress has been made in understanding iron homeostasis by characterising the role of the iron-regulating hormone hepcidin, the effects of ID on skeletal and cardiac myocytes, kidneys and the immune system.

iron deficiency iron metabolism heart failure pathophysiology

1. Introduction

1.1. Physiologic Roles and Regulation of Iron

Iron is an essential cofactor for the normal functioning of many enzymes participating in vital cellular and organismal functions, making it indispensable for every living cell [1][2][3]. In addition to its important role in oxygen transport and storage as a constituent of hemoglobin and myoglobin respectively, iron is crucial for many enzymes and proteins involved in oxidative metabolic processes (e.g., mitochondrial respiratory chain, oxidative enzymes and protection against oxidative stress), microRNA biogenesis, the function of the thyroid gland, central nervous system and immune system [1][2][4]. Furthermore, iron is crucial for the synthesis and degradation of proteins, lipids (e.g., β-oxidation of fatty acids), carbohydrates, DNA and RNA [4][5][6][7][8]. Of note, iron is particularly important for cells either with high energy demand (cardiomyocytes, hepatocytes, neurons, renal and skeletal cells) or high mitogenic activity (e.g., haematopoietic and immune cells) [9][10]. Accordingly, these cells are more sensitive to Iron deficiency (ID) [9]. An overview of the functions and proteins that require iron are outlined in Figure 1 and Table 1 [10][11][12], respectively.
Jcm 11 00125 g001
Figure 1. Overview of the multifaceted roles of iron in diverse organs and molecular processes. TCA: tricarboxylic acid cycle; miRNA: microRNA, ROS: reactive oxygen species (Created with BioRender.com, accessed on 24 November 2021).
Table 1. Overview of proteins that require iron to function properly.
Function Protein
Oxygen transport Hemoglobin
Oxygen storage Myoglobin
Lipid and cholesterol biosynthesis NADPH-cytochrome P450 reductase, fatty acid desaturases, cytochrome P-450 subfamily 51 and Cytochrome P450 Family 7 Subfamily A Member 1
Oxygen sensing and regulation of hypoxia Hypoxia-inducible factor prolyl hydroxylases
Synthesis catecholamines and neurotransmitters Tryptophan hydroxylase, tyrosine hydroxylase, monoamine oxidase and aldehyde oxidase
Host defence, inflammation and production of nitric oxide Myeloperoxidase, NADPH oxidase, indoleamine 2,3- dioxygenase, nitric oxide synthase and lipoxygenases
DNA synthesis, replication and repair Ribonucleotide reductases, DNA polymerases, DNA glycolsylases, DNA primases, DNA helicasess and DNA endonucleases. Dihydropyrimidine dehydrogenas
Collagen synthesis Proline hydroxylase
Electron transport and respiratory chain Cytochrome C oxidase, Cytochrome b, cytochrome c1, Cytochrome oxidase P540, NADH dehydrogenase, aconitase, citrate synthase, Succinyl dehydogease, cytochrome reductase, Complex I-III, rieske protein, NADH ferrocyanide oxidoreductase
Adrenoxin Steroid hydoxylation
Antioxidant defence Catalase
Response to oxidative stress Glutathione peroxidase 2, lactoperoxidase
Amino acid metabolism Tryptophan pyrrolase, Phenaylalanine hydroxylase, deoxyhypusine hydroxylase
Carnitine biosynthesis α-ketoglutarate (αKG)-dependent oxygenases
Synthesis of thyroid hormone Thyroid peroxidase
Drug detoxification Cytochrome P450 , NADPH cytochrome P450 reductase
Prostaglandin thromboxane synthesis, inflammation and response to oxidative stress Cyclooxyenase
microRNA biogenesis DiGeorge Syndrome Critical Region Gene 8
Ribosome function and tRNA modification ABCE1, CDKRAP1, TYW1 and CDKAL1, Methylthiotransferase
Haeme biosynthesis Ferrochelatase
Apoptosis and oxygen transport in the brain Neuroglobin
Purine metabolism and synthesis Xanthine oxidase, amidophosphoribosyltransferase
Besides its crucial roles in the body, iron is a potentially harmful element to cells given its chemical reactivity and its propensity to generate reactive oxygen species through participating in Fenton’s reaction [1][10]. Iron is almost always linked to either ferritin intracellularly or extracellularly to transferrin as free iron ions are toxic [1]. In addition, iron status is tightly regulated both systematically by hepcidin and cellularly through iron-regulatory proteins. A comprehensive overview of cellular and systemic iron metabolism can be found elsewhere [12][13][14][15].

1.2. Definition of Iron Deficiency

ID ensues when iron supply is insufficient to meet the body’s needs or to cover the iron lost physiologically or pathologically [5]. ID may manifest itself in two distinct forms with intertwined pathophysiology, namely functional and absolute ID. Absolute ID (AID) reflects depleted iron stores, while functional ID (FID) is characterised by reduced availability of iron despite sufficient or overly abundant iron stores due to suboptimal iron trafficking induced by hepcidin. It is crucial to note that studies in HF differ in defining ID [16][17][18][19]. The most widely used definition of ID, which is also adopted by the European Society of Cardiology (ESC), is a ferritin level <100 μg/L (reflecting AID) or ferritin (100 to 300 μg/L) with a transferrin saturation (TSAT) <20% (reflecting FID) [20]. This definition of ID has, however, been criticised as it has never been validated against a gold standard and remains a subject of considerable debate, especially in patients with acute HF [17][18][21][22][23][24].
The ESC definition of ID (also called the FAIR-HF definition [25]) is limited by relying heavily on ferritin levels, thereby labelling patients with TSAT ≤20%, but a ferritin >300 μg/mL as iron sufficient, while labelling those with isolated hypoferritinaemia (ferritin <100 μg/mL with a TSAT >20%) as iron deficient. This latter category was found to be iron sufficient when compared to bone marrow staining, the golden standard for diagnosing ID [23]. Although ferritin is one of the most widely used biomarkers to detect iron deficiency [26], serum ferritin levels can be profoundly influenced by several factors such as inflammation, infection and malignancy, making it falsely elevated in an inflammatory state such as HF and thus does not correlate with iron availability [27]. Herein showed that, compared to bone marrow iron staining, the ESC definition of ID has a sensitivity of 82.4% and a specificity of 72% for detecting ID in patients with HF [23]. Serum iron (≤13 μmol/L) and TSAT (≤19.8%) were significantly better cutoffs than the FAIR-HF definition, with areas under the curves (AUC) of 0.922 and 0.932, respectively. Adding ferritin to either definition did not result in a significant increase in the AUC, suggesting that ferritin does not contribute to more accurate identification of truly iron deficient HF patients, and as such, both serum iron ≤13 μmol/L and TSAT ≤19.8% are good indicators of ID as standalone. Prognostically, these two definitions are independently associated with a higher incidence of all-cause mortality, while isolated hypoferritinemia did not [23]. Several studies corroborated these findings [16][17][19][23][28][29][30]. More recently, it was found that persistent ID (defined as a serum iron ≤13 µmol/L) was associated with poor prognosis, while its resolution was associated with improved outcomes. Similar trends were found when defining ID as TSAT <20%, but not when defined as per the FAIR-HF criteria [17]. Remarkably, Cleland et al. found that higher ferritin levels (and not lower levels) were significantly associated with a higher risk of all-cause or cardiovascular mortality, further questioning the correlation between ferritin and iron availability in patients with HF. Additionally, subgroup analysis of individual patient data meta-analysis (n = 839) pooled from four double-blind, randomised controlled trials (RCTs) showed that although intravenous ferric carboxymaltose (FCM) generally reduces recurrent cardiovascular hospitalisations and cardiovascular mortality, patients with TSAT <20.1% benefit more from FCM iron than those with TSAT >20.1% even if ferritin levels were low [31]. Similarly, in the IRON-CRT trial, it was found that HF patients with TSAT <20% benefit more from FCM iron than if TSAT was >20% in terms of cardiac contractility and left ventricular ejection fraction (LVEF) [32]. However, similar interaction was not found in the AFFIRM-AHF trial [33]. The aforementioned findings confirm the accuracy of TSAT <20% and serum iron ≤13 µmol/L in identifying truly iron deficient HF patients while questioning the diagnostic and prognostic usage of ferritin in detecting ID in HF.
On the other hand, these two definitions of ID might have their own limitations, as serum iron is subjected to circadian variations [34], and TSAT might be falsely elevated in malnutrition and advanced stages of renal insufficiency [18][35][36][37]. Recent studies proposed serum soluble transferrin receptor (sTfR) as the most auspicious novel ID-related biomarker since circulating sTfR levels reflect the iron demand of the body in addition to the erythroid proliferation rate quantitatively [38]. In a similar approach to the bone marrow study, Sierpinski et al. found that ID defined as serum sTfR of ≥1.25 mg/L is more accurate in identifying ID when compared to bone marrow staining in clinically stable patients with HF [24]. Of note, adding sTfR to multivariable models for predicting 3-year all-cause mortality in patients with HF abolishes the prognostic value of serum ferritin and TSAT after adjusting for all other prognosticators. These findings suggest that elevated serum sTfR is a better surrogate for depleted intracellular iron. In line with these findings, Leszek et al. found that only serum sTfR significantly correlated to myocardial and mitochondrial iron status, but not ferritin, serum iron or TSAT [39], indicating that sTfR reflects tissue iron demands more accurately. Nevertheless, the lack of assay standardisation restricts its implementation in clinical routines [37].
To summarise, defining ID in HF using classical biochemical iron parameters appears to be not straightforward. Mounting evidence suggests that ferritin should not be taken into consideration when diagnosing ID in patients with HF but may be used as a safety parameter to avoid the administration of iron to patients with potential iron overload; TSAT or serum iron alone are better indicators of systemic ID, while sTfR might outperform them all. Although the current ESC definition of ID performed thus far reasonably good in general, it is broad and unspecific in identifying those who are truly iron deficient; the high prevalence of ID in HF might have precluded the importance of choosing a more accurate definition to identify those who are truly iron deficient and need IV iron. Identifying truly iron-deficient patients is crucial as inaccurate diagnoses of ID [17] and unnecessary treatment with FCM might dilute the benefits of IV iron and lead to increased risks such as hypophosphatemia [40]. Furthermore, in light of existing evidence indicating different mechanisms leading to myocardial and systemic ID [41] (as discussed below) as well as poor accuracy of systemic biomarkers in detecting myocardial ID, which might be a major driver behind clinical improvements upon iron supplementation, future studies should evaluate other ID-related surrogates in order to identify HF patients that might benefit from iron supplementation on a systemic and cellular level.

2. Deleterious Biological Consequences of Iron Deficiency

The functional and clinical impairments as well as the benefits of correcting ID observed in non-anaemic iron-deficient HF patients point towards the important role of iron in nonhematopoietic tissues [42][43][44][45][46][47]. The underlying mechanisms between the worst symptomatic status and prognosis remain poorly characterised. Recent years sparked an avalanche of research seeking to explain the mechanisms by which ID contributes to these adverse effects. In order to understand the consequences of ID in HF patients beyond anaemia, consideration should be directed towards the roles of iron beyond mere erythropoiesis. In the following sections, the cellular and subcellular effects of ID are discussed. A summary of the deleterious effects of ID is shown in Figure 2.
Jcm 11 00125 g003
Figure 2. Overview of the biological consequences of iron deficiency. NTproBNP: N-terminal pro-b-type natriuretic peptide; OXPHOS: Oxidative phosphorylation; RNS: reactive nitrogen species; ROS: reactive oxygen species and FGF23: Fibroblast growth factor-23 (Created with BioRender.com, accessed on 24 November 2021).

2.1. Mitochondrial Function and Metabolic Effects

Cells with high energy demand such as cardiomyocytes, hepatocytes, nephrons and skeletal myocytes are abundant with mitochondria. Mitochondria are the major intracellular sites of iron utilisation and accumulation as they are the sites where synthesis of haeme and iron–sulphur clusters takes place [48][49]. Beyond its biosynthetic role in haeme and iron–sulphur clusters, iron was also shown to be crucial for mitochondrial biogenesis as ID affects both iron-containing and non-iron-containing mitochondrial proteins, indicating a reciprocal relationship between adequate iron content and mitochondrial function [50].
Mitochondria are the primary combustion machinery in cells for burning fuel such as glucose, fatty acids and ketone bodies. The final step to producing adenosine triphosphate (ATP) from these nutrients is oxidative phosphorylation (OXPHOS), for which sufficient iron (in addition to other pathways) is vital. This fact highlights how crucial iron is for proper energetics in all cells.
Besides producing ATP, mitochondria are also involved in controlling cellular Ca2+ [51], generating reactive oxygen species, cellular death, synthesis of pyrimidine, amino acids and lipids [48]. Accordingly, deficiency in iron impairs mitochondrial function at many levels. ID has been linked to morphological changes in the mitochondria, such as an increase in size and a decrease in cristae [52], as well as functional changes such as reduced production of ATP [53], mitochondrial DNA damage [52], increased gluconeogenesis [48][54], increased lactic acid production [46][47][55], reduced mitochondrial biogenesis and impaired mitophagy [56][50], increased mitochondrial cytochrome c release (and hence apoptosis) and reactive nitrogen species expression [57][58][59][60][61][62]. All of this culminates in mitochondrial damage. As such, ID may worsen HF by causing mitochondrial damage [63][64], and its correction augments mitochondrial function.
Oxidative Stress
Mitochondria are the primary source of production and scavenging of both reactive oxygen species (ROS) and reactive nitrogen species (RNS) [65][66]. Not only can iron excess lead to oxidative stress via Fenton-type reactions but ID was also shown to promote oxidative and nitrosative stress [66]. This is thought to be related to the reduced antioxidant activity (e.g., catalase enzyme) [67] and increased superoxide production as a result of mitochondrial dysfunction. In the heart samples of HF patients undergoing transplantation, myocardial ID is associated with reduced expression of key protective enzymes that scavenge ROS, such as catalase, glutathione peroxidase and superoxide dismutase 2 [68]. This may point towards ROS and/or RNS induction as an adverse consequence of ID, which is seen as one of the underlying mechanisms leading to myocardial remodeling and HF progression [69]. Toblli et al. showed that even without completely correcting anaemia, IV iron sucrose reversed the anaemia-induced cardiac remodeling, prevented cardiac fibrosis and improved cardiac function by mitigating oxidative/nitrosative stress and inflammation in the heart [70]. Furthermore, in another rat model of HF, intravenously administering iron resulted in higher tissue activity of the antioxidant superoxide dismutase [71]. A recent study found similar results in a mice model of myocardial infarction [72]. Several studies showed that ID participates in the induction of oxidative stress in many organs, including the liver and the kidneys [73][74]. All in all, ID makes cells more prone to oxidative/nitrosative damage, and its correction may ameliorate these adverse effects of ID.

2.2. Heart

Since the heart has the highest energy expenditure of all organs [75], intact performance of cardiomyocytes is inextricably linked to mitochondrial function, for which sufficient iron is vital. This makes cardiomyocytes especially susceptible to the adverse effects of ID. Depriving human cardiomyocytes of iron leads to impaired contractile function with reduced activity of respiratory complexes I, II and III [53]. Remarkably, these adverse effects of ID can be reversed by iron supplementation. Similarly, several animal studies showed that systemic ID, even without anaemia [76], is associated with structural changes in the heart, including cardiac hypertrophy, irregular sarcomere organisation, mitochondrial swelling, left ventricular(LV) dilation , LV hypertrophy, lung congestion and cardiac fibrosis [57][77][78][79]. In addition to structural remodelling, the hearts of mice with IDA exhibit a hypoxic phenotype and altered Ca2+ handling, with a metabolic shift towards lactic acid-producing glycolytic metabolism [46][80]. Furthermore, hearts of mice models with isolated myocardial ID without anaemia develop cardiomegaly, impaired contractile function, shifts towards anaerobic respiration, dysfunctional oxidative phosphorylation and impaired mitophagy despite normal systemic iron levels [81][56].
Failing human hearts are characterised by reduced total iron content [40][54][82]. Systemic ID and/or myocardial ID is associated with worse cardiac function, diminished contractile reserve [83], decreased mitochondrial enzymatic activities of both oxidative phosphorylation and anti-oxidative enzymes [40][84][53][54]. When taken together, these studies highlight the importance of normal iron content to the heart and that its deficiency could play a causal role in the pathogenesis of systolic and diastolic myocardial dysfunction as well as HF progression independently of systemic iron status.
Replenishing iron prevents abnormalities of Ca2+ handling, improves cardiac function and survival in rat models with HF [85]. In the Myocardial-IRON Trial, it was found that administering FCM intravenously in iron-deficient HF patients resulted in significant improvement in cardiac magnetic resonance sequences, indicating myocardial iron repletion [86]. This correction of ID was accompanied by improved right and left ventricular ejection fraction on the 7th day already [87]. Several other studies corroborate these positive echocardiographic effects of IV on the heart [79][88][89][90][91]. Remarkably, in HFrEF patients receiving cardiac resynchronisation therapy (CRT), the presence of ID is associated with diminished reverse remodelling and lesser likelihood of functional improvement after CRT implementation, suggesting that adequate myocardial iron content is a prerequisite to derive optimal benefits from CRT implantation with respect to reverse cardiac remodelling and improved cardiac function [92][93]. In line with these findings, the recent IRON-CRT trial showed that IV iron repletion reverses myocardial remodelling and boosts cardiac performance and contractility in patients receiving CRT, which were also accompanied by improvements in quality of life and exercise capacity [32]. These results demonstrate the incremental potential of IV iron in reverse cardiac remodelling in addition to guideline-directed therapies that induce reverse remodelling [94]. Whether IV iron can prevent myocardial remodelling inflicted by either ischaemic or non-ischaemic damage is not known. It is worth noting that although beneficial effects of IV iron on the failing heart are indubitable, some research indicates that mitochondrial iron chelation might also have beneficial effects for patients with HF [95][82][96][97]. Further work is needed to delineate the effects of IV iron both systemically and cellularly.

2.3. Skeletal Muscles

Exercise intolerance is a cardinal symptom of HF, with impaired oxidative metabolism, decreased blood perfusion to skeletal muscles and oxygen delivery implicated as potential causes [98]. Mitochondrial dysfunction inflicted by ID is not limited to the heart but extends to other organs, especially those with high energy demands such as skeletal muscles. Intuitively, decreased exercise capacity in ID is linked to defective O2 delivery due to anaemia. However, deficiency of iron impairs skeletal muscle function also by anaemia-independent pathways, which is oxidative metabolism and oxygen storage in myoglobin [10][99]. Several animal studies have shown that impaired exercise capacity is directly linked to ID due to diminished mitochondrial energy metabolism [10][100]. Even when hemoglobin levels were kept constant, iron-deficient animals showed a significantly lower exercise capacity accompanied by impaired oxidative metabolism, indicating a direct relationship between ID and impaired physical performance irrespective of anaemia [101][102]. A meta-analysis in athletes with isolated ID without anaemia showed that iron therapy improves systemic iron status and their aerobic capacity as evaluated using maximal oxygen consumption (VO2 max) [103]. Furthermore, in a knockout mice model of Tfr1 specifically to skeletal muscles, Barrientos et al. showed that isolated muscle ID had profound systemic metabolic effects besides impaired mitochondrial respiration in muscles, suggesting that muscle ID may have unrecognised effects on systemic energy homeostasis [104].
In patients with HF, results of the FAIR-HF, CONFIRM-HF and EFFECT-HF randomised controlled trials all indicate that iron repletion improved exercise capacity irrespective of attained hemoglobin levels [25][45][105]. Melenovsky et al. showed that iron-deficient HF patients exhibit more severe skeletal muscle myopathy than their iron-sufficient counterparts as assessed using Phosphorus-31 magnetic resonance spectroscopy (31P MRS). By using the same approach, Charles-Edwards et al. showed that in iron-deficient HFrEF, IV iron isomaltoside significantly shortens phosphocreatine regeneration after exercise despite no change in haemoglobin levels, indicating enhanced skeletal muscle energetics already by 2 weeks [106]. Boosting skeletal muscle energetics seems to be an important mechanism by which correcting ID leads to beneficial outcomes in patients with HF.

2.4. Kidneys

The kidneys are another high-energy-demanding organ system with high mitochondrial content [107]. From an energetics perspective, reabsorption and secretion of solutes in the nephrons occur either passively or actively (e.g., Na+/K+-ATPase), with the latter requiring energy for proper functioning. As such, iron, due to its crucial role in the mitochondria, is important for kidney function [108]. Although ID is mostly seen as a consequence of renal diseases, several studies suggest that iron itself influences kidney function [109]. A recent Mendelian randomisation study investigated the causal effect of serum iron levels on kidney function in the general population. They found a 1.3% increase in estimated glomerular filtration rate per standard deviation increase in serum iron (95% confidence interval 0.4–2.1%; p = 0.004), indicating a protective effect of higher iron levels on renal function [110]. In accordance with these findings, feeding rats an iron-deficient diet resulted in an increase in malondialdehyde (an indicator of increased lipid peroxidation) in the kidneys, suggesting that ID can also adversely affect the kidney through oxidative stress and mitochondrial dysfunction [73]. In children, ID was shown to be associated with tubular and glomerular damage accompanied by increased oxidative stress markers [111]. Whether ID has similar direct effects on the kidneys in patients with HF is unknown.
In patients with HF, Toblli et al. showed that IV iron in anaemic HF patients with CKD resulted in a significant improvement in renal function [112]. Similarly, in a sub-analysis of the FAIR-HF trial, it was found that patients in the FCM group had an improved kidney function as evaluated by estimated Glomerular Filtration Rate (eGFR) [113]. This improvement in renal function was observed in all pre-specified subgroups, including HF patients with preserved renal function and those without anaemia. Remarkably, correcting ID might be associated with a reduction in fibroblast growth factor 23 (FGF23) [114][115], which was linked with worse clinical outcomes in both HF and renal disease [116]. This suggests that the benefits of IV iron on the kidneys may extend beyond its effects on the energetics of renal mitochondria. Future studies should look into the interaction between FGF23, iron status, heart and kidneys since FGF23 has been shown to decrease hepcidin expression [117], in addition to acting as a mediator between ID and its association with mortality in patients with HF [118].
Altogether, treating ID in HF patients may pose renoprotection properties. Data on the effects of ID on the kidneys are scarce. Further studies are therefore warranted. Moreover, given the established role of the kidneys in controlling systemic iron levels [109], it is yet to be ascertained whether impaired kidney function could increase urinary iron excretion and thereby cause ID in HF.

2.5. The Immune System

Beyond the cardiocentric perspective, iron homeostasis is also important for the immune system [10]. The relationship between iron and immunity is complex and bidirectional. As alluded to earlier, inflammation as an immune effector mechanism can lead to iron dysmetabolism, but iron dysmetabolism itself also causes adverse changes in immune function [119][120].
ID can affect the immune system in multiple ways. ID negatively affects both the growth and effector mechanisms of the immune system. Deleterious effects of ID include reduced neutrophil activity (myeloperoxidase is iron-dependent), reducing functions of nuclear factor kappa and HIFs, nitric oxide (NO) formation, a defective proliferation of T cells (especially T helper 1 cells) [121] and impaired interleukin 2 production [11][122][123]. Howden et al. showed that activated CD4+ and CD8+ T-cells upregulate their transferrin receptor, suggesting that iron is important for T-cell activation [124]. In mice fed an iron-deficient diet, altered T lymphocyte and natural killer (NK) cell activity was demonstrated, indicating impaired cellular mediated immunity [125][126].
Contrary to the overly simplistic view where ID is merely seen as a consequence of inflammation, studies showed that ID could perpetuate and amplify inflammation [127]. ID in mice induces and enhances inflammation when compared to mice with normal iron status [128]. A recent study in a rat post-myocardial infarction (MI) HF model showed that iron supplementation (FCM) reduces inflammation [71]. This dampening effect of iron is thought to be due to the important role of iron for immune cells to mount an effective immune response. In fact, more than 10 years ago, Toblli et al. showed that administration of iron sucrose intravenously in anemic HF patients led to a significant reduction in C-reactive protein [112]. Other studies corroborated this evidence [70]. When taken together, these results support the idea that ID itself can also have a direct adverse effect on the immune system and that its correction has advantages beyond merely stimulating erythropoiesis.

2.6. The Brain

Mental functions have biochemical bases, and hence dysregulation herein can lead to mental effects. A growing body of evidence suggests that iron is important for neurological functions as the brain is also a metabolically active organ, making it particularly susceptible to ID [129]. In addition to energy deficits of neural cells, ID can also impair synaptic plasticity, myelination and reduce the activity of multiple iron-dependent enzymes involved in dopamine and serotonin synthesis (monoamine oxidase, tyrosine hydroxylase and tryptophan hydroxylase) [130][131]. Several studies showed that brain ID leads to deficits in memory, learning, behaviour and emotional problems [132]. Low levels of serotonin due to ID may lead to a relapse of depression [133]. Psychological disorders such as depression are very common in HF patients [134]. Several studies reported a higher prevalence of depression in iron-deficient HF [9][135][136]. Whether systemic ID is associated with brain ID in HF patients is unknown. Moreover, the effects of IV iron in patients with HF on mental functioning have not been assessed yet.

2.7. Thyroid Gland

Accumulated evidence shows that thyroid dysfunction is linked with an increased risk for and worsening of HF [20][137][138]. ID impairs thyroid hormone metabolism by different mechanisms, including ineffective erythropoiesis, reduced thyroid peroxidase activity (haeme-containing enzyme) and increased hepatic inactivation of thyroid hormones [139][140]. Iron deficient HFpEF patients have a significantly higher prevalence of thyroid disease [135]. The therapeutic consequence of replenishing iron on thyroid function in HF has not been studied yet.

3. Novel Therapeutic Options for Targeting Iron Metabolism

Although iron replacement therapy remains to be the cornerstone of treating ID in HF, several experimental iron metabolism-targeting agents have been developed to treat IDA, many of which were evaluated in patients with CKD and cancer-related anaemia [141]. These treatment options increase iron absorption as well as the mobilisation of sequestered iron by either downregulating the synthesis and/or function of hepcidin or by stabilising HIFs as a result of Prolyl-4-hydroxylases (PHDs) inhibition [117].
Manipulation of the hepcidin–ferroportin axis seems an attractive target as the interplay between hepcidin and ferroportin is crucial for regulating iron status and aberrations in this pathway are centrally involved in the pathophysiology of FID [142]. Targeting hepcidin directly (e.g., LY2787106, Lexaptepid pegol or Anticalins), or indirectly by targeting inflammatory markers (e.g., IL-6), bone morphogenic protein 6 (BMP6) [LY3113593], was proposed as a treatment option for anaemia of inflammation as these agents were shown to increase intestinal iron absorption and mobilisation in phase 1 and/or 2 studies [117]. Moreover, blocking hepcidin’s interaction with ferroportin using ferroportin antibodies (LY2928057) reduces ferroportin internalisation, thereby increasing mobilisation of sequestered iron from the reticuloendothelial system [143]. Manipulation of the hepcidin pathway in inflammatory conditions such as HF might be a compelling option to treat ID in HF besides targeting inflammation, especially in those with FID as they have clear inflammatory components accompanied by high hepcidin levels [84]. In a recent phase 1/2 clinical trial, Pergola et al. showed that administration of ziltivekimab, anti-IL-6 ligand antibody, led to a dose-dependent improvement in serum iron, TSAT, inflammatory markers and reduction in hepcidin in CKD patients on haemodialysis with hyporesponsiveness to erythropoiesis-stimulating agents [144]. Whether targeting inflammation by reducing IL-6 activity and thereby improving clinical outcomes and iron metabolism can also be a therapeutic option to patients with HF is unknown.
Another promising approach is the manipulation of the prolyl hydroxylase domain/hypoxia-inducible factor (PHD/HIF) pathway, which seems to be deranged in iron-deficient patients with HF [145][46]. Several HIFs stabilisers are being developed, some of which have entered/finished phase 3 of clinical trials, including Vadadustat, Daprodustat and Roxadustat [146]. Meta-analyses of several randomised controlled trials showed that PHD inhibitors increase the levels of hemoglobin, serum transferrin and increase intestinal iron absorption while reducing levels of hepcidin in anaemic CKD patients [146][147][148]. These effects seem to be independent of inflammation [146]. Such activation of HIF signalling can provide a physiologic approach towards improved iron metabolism and may complement and/or reduce the need for IV iron in iron-deficient patients with HF. Besides being orally administered, targeting this pathway may have other non-erythopoetic benefits, such as lowering cholesterol levels as well as blood pressure [149][150]. However, there are many concerns regarding its safety as stabilising HIFs might lead to unwanted effects such as promoting cancer development since HIFs modulate the expression of various proteins that are involved in energy metabolism, angiogenesis, cellular growth and differentiation [117]. Large, carefully designed, long-term clinical trials are required to clearly understand the effects of systemic activation of the HIF pathway on iron-deficient HF patients.
Lastly, it should be noted that these agents can mainly increase absorption or mobilisation of sequestered iron, making them potentially ineffective for patients who have AID. Whether targeting the PHD/HIF or hepcidin–ferroportin axes have additive or possibly even synergistic effects with IV iron to correct ID, improve iron mobilisation in a more physiological manner and prevent relapses of ID remains to be investigated.

4. Conclusions

The consequences of ID per se reach far beyond those of anaemia. Energy deficit is one of the hallmarks of HF. Mounting evidence indicates that mitochondrial dysfunction is a prominent repercussion of ID, which further aggravates the existing deficit in energy in HF. Current standard-of-care pharmacological approaches to HF provide symptomatic and clinical benefits by reducing the workload on the heart instead of increasing its reserve. Targeting ID in HF can improve the care of HF patients as it addresses this shortcoming by augmenting mitochondrial function. This makes ID stand out as a therapeutic target in HF since it is relatively easy to diagnose and treat with potential anti-remodelling effects.

References

  1. Muckenthaler, M.U.; Rivella, S.; Hentze, M.W.; Galy, B. A Red Carpet for Iron Metabolism. Cell 2017, 168, 344–361.
  2. Andrews, N.C.; Schmidt, P.J. Iron homeostasis. Annu. Rev. Physiol. 2007, 69, 69–85.
  3. Cairo, G.; Bernuzzi, F.; Recalcati, S. A precious metal: Iron, an essential nutrient for all cells. Genes Nutr. 2006, 1, 25–39.
  4. Ponka, P.; Schulman, H.M.; Woodworth, R.C.; Richter, G.W. Iron Transport and Storage; CRC Press: Boca Raton, FL, USA, 2000.
  5. Pasricha, S.R.; Tye-Din, J.; Muckenthaler, M.U.; Swinkels, D.W. Iron deficiency. Lancet 2021, 397, 233–248.
  6. Partin, A.C.; Ngo, T.D.; Herrell, E.; Jeong, B.C.; Hon, G.; Nam, Y. Heme enables proper positioning of Drosha and DGCR8 on primary microRNAs. Nat. Commun. 2017, 8, 1737.
  7. Zhang, C. Essential functions of iron-requiring proteins in DNA replication, repair and cell cycle control. Protein Cell 2014, 5, 750–760.
  8. Ponikowski, P.; Kirwan, B.A.; Anker, S.D.; Dorobantu, M.; Drozdz, J.; Fabien, V.; Filippatos, G.; Haboubi, T.; Keren, A.; Khintibidze, I.; et al. Rationale and design of the AFFIRM-AHF trial: A randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. Eur. J. Heart Fail. 2019, 21, 1651–1658.
  9. Jankowska, E.A.; Von Haehling, S.; Anker, S.D.; MacDougall, I.C.; Ponikowski, P. Iron deficiency and heart failure: Diagnostic dilemmas and therapeutic perspectives. Eur. Heart J. 2013, 34, 816–829.
  10. Beard, J.L. Iron biology in immune function, muscle metabolism and neuronal functioning. J. Nutr. 2001, 131, 568S–580S.
  11. Zohora, F.; Bidad, K.; Pourpak, Z.; Moin, M. Biological and Immunological Aspects of Iron Deficiency Anemia in Cancer Development: A Narrative Review. Nutr. Cancer 2018, 70, 546–556.
  12. Hentze, M.W.; Muckenthaler, M.U.; Galy, B.; Camaschella, C. Two to Tango: Regulation of Mammalian Iron Metabolism. Cell 2010, 142, 24–38.
  13. Silva, B.; Faustino, P. An overview of molecular basis of iron metabolism regulation and the associated pathologies. Biochim. Biophys. Acta—Mol. Basis Dis. 2015, 1852, 1347–1359.
  14. Ganz, T. Systemic iron homeostasis. Physiol. Rev. 2013, 93, 1721–1741.
  15. Lawen, A.; Lane, D.J.R. Mammalian iron homeostasis in health and disease: Uptake, storage, transport, and molecular mechanisms of action. Antioxidants Redox Signal. 2013, 18, 2473–2507.
  16. Cleland, J.G.F.; Zhang, J.; Pellicori, P.; Dicken, B.; Dierckx, R.; Shoaib, A.; Wong, K.; Rigby, A.; Goode, K.; Clark, A.L. Prevalence and outcomes of anemia and hematinic deficiencies in patients with chronic heart failure. JAMA Cardiol. 2016, 1, 539–547.
  17. Graham, F.J.; Masini, G.; Pellicori, P.; Cleland, J.G.F.; Greenlaw, N.; Friday, J.; Kazmi, S.; Clark, A.L. Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure. Eur. J. Heart Fail. 2021.
  18. Jankowska, E.A.; Kasztura, M.; Sokolski, M.; Bronisz, M.; Nawrocka, S.; Oleśkowska-Florek, W.; Zymliński, R.; Biegus, J.; Siwołowski, P.; Banasiak, W.; et al. Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. Eur. Heart J. 2014, 35, 2468–2476.
  19. Van der Wal, H.H.; Grote Beverborg, N.; Dickstein, K.; Anker, S.D.; Lang, C.C.; Ng, L.L.; van Veldhuisen, D.J.; Voors, A.A.; van der Meer, P. Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use. Eur. Heart J. 2019, 40, 3616–3625.
  20. McDonagh, T.A.; Metra, M.; Adamo, M.; Gardner, R.S.; Baumbach, A.; Böhm, M.; Burri, H.; Butler, J.; Čelutkienė, J.; Chioncel, O.; et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2021, 42, 3599–3726.
  21. Martens, P.; Grote Beverborg, N.; van der Meer, P. Iron deficiency in heart failure—Time to redefine. Eur. J. Prev. Cardiol. 2020, zwaa119.
  22. Ueda, T.; Kawakami, R.; Nogi, K.; Nogi, M.; Ishihara, S.; Nakada, Y.; Nakano, T.; Hashimoto, Y.; Nakagawa, H.; Nishida, T.; et al. Serum iron: A new predictor of adverse outcomes independently from serum hemoglobin levels in patients with acute decompensated heart failure. Sci. Rep. 2021, 11, 2395.
  23. Beverborg, N.G.; Klip, I.T.; Meijers, W.C.; Voors, A.A.; Vegter, E.L.; Van Der Wal, H.H.; Swinkels, D.W.; Van Pelt, J.; Mulder, A.B.; Bulstra, S.K.; et al. Definition of iron deficiency based on the gold standard of bone marrow iron staining in heart failure patients. Circ. Heart Fail. 2018, 11, e004519.
  24. Sierpinski, R.; Josiak, K.; Suchocki, T.; Wojtas-Polc, K.; Mazur, G.; Butrym, A.; Rozentryt, P.; Meer, P.; Comin-Colet, J.; Haehling, S.; et al. High soluble transferrin receptor in patients with heart failure: A measure of iron deficiency and a strong predictor of mortality. Eur. J. Heart Fail. 2021, 23, 919–932.
  25. Anker, S.D.; Comin Colet, J.; Filippatos, G.; Willenheimer, R.; Dickstein, K.; Drexler, H.; Lüscher, T.F.; Bart, B.; Banasiak, W.; Niegowska, J.; et al. Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. N. Engl. J. Med. 2009, 361, 2436–2448.
  26. Mei, Z.; Cogswell, M.E.; Parvanta, I.; Lynch, S.; Beard, J.L.; Stoltzfus, R.J.; Grummer-Strawn, L.M. Hemoglobin and ferritin are currently the most efficient indicators of population response to iron interventions: An analysis of nine randomized controlled trials. J. Nutr. 2005, 135, 1974–1980.
  27. Dignass, A.; Farrag, K.; Stein, J. Limitations of Serum Ferritin in Diagnosing Iron Deficiency in Inflammatory Conditions. Int. J. Chronic Dis. 2018, 2018, 9394060.
  28. Palau, P.; Llàcer, P.; Domínguez, E.; Tormo, J.P.; Zakarne, R.; Mollar, A.; Martínez, A.; Miñana, G.; Santas, E.; Almenar, L.; et al. Iron deficiency and short-term adverse events in patients with decompensated heart failure. Clin. Res. Cardiol. 2021, 110, 1292–1298.
  29. Gentil, J.R.d.S.; Fabricio, C.G.; Tanaka, D.M.; Suen, V.M.M.; Volpe, G.J.; Marchini, J.S.; Simões, M.V. Should we use ferritin in the diagnostic criteria of iron deficiency in heart failure patients? Clin. Nutr. ESPEN 2020, 39, 119–123.
  30. Moliner, P.; Jankowska, E.A.; van Veldhuisen, D.J.; Farre, N.; Rozentryt, P.; Enjuanes, C.; Polonski, L.; Meroño, O.; Voors, A.A.; Ponikowski, P.; et al. Clinical correlates and prognostic impact of impaired iron storage versus impaired iron transport in an international cohort of 1821 patients with chronic heart failure. Int. J. Cardiol. 2017, 243, 360–366.
  31. Anker, S.D.; Kirwan, B.-A.; van Veldhuisen, D.J.; Filippatos, G.; Comin-Colet, J.; Ruschitzka, F.; Lüscher, T.F.; Arutyunov, G.P.; Motro, M.; Mori, C.; et al. Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: An individual patient data meta-analysis. Eur. J. Heart Fail. 2018, 20, 125–133.
  32. Martens, P.; Dupont, M.; Dauw, J.; Nijst, P.; Herbots, L.; Dendale, P.; Vandervoort, P.; Bruckers, L.; Tang, W.H.W.; Mullens, W. The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy—the IRON-CRT trial. Eur. Heart J. 2021, ehab411.
  33. Ponikowski, P.; Kirwan, B.-A.; Anker, S.D.; McDonagh, T.; Dorobantu, M.; Drozdz, J.; Fabien, V.; Filippatos, G.; Göhring, U.M.; Keren, A.; et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: A multicentre, double-blind, randomised, controlled trial. Lancet 2020, 396, 1895–1904.
  34. Cao, G.Y.; Li, Y.; Jin, P.F.; Hu, X. Circadian rhythm in serum iron levels. Biol. Trace Elem. Res. 2012, 147, 63–66.
  35. Tomasz, G.; Ewa, W.; Jolanta, M. Biomarkers of iron metabolism in chronic kidney disease. Int. Urol. Nephrol. 2021, 53, 935–944.
  36. Yu, P.H.; Lin, M.Y.; Chiu, Y.W.; Lee, J.J.; Hwang, S.J.; Hung, C.C.; Chen, H.C. Low serum iron is associated with anemia in CKD stage 1–4 patients with normal transferrin saturations. Sci. Rep. 2021, 11, 8343.
  37. Pfeiffer, C.M.; Looker, A.C. Laboratory methodologies for indicators of iron status: Strengths, limitations, and analytical challenges. Am. J. Clin. Nutr. 2017, 106, 1606S–1614S.
  38. Manckoundia, P.; Konaté, A.; Hacquin, A.; Nuss, V.; Mihai, A.M.; Vovelle, J.; Dipanda, M.; Putot, S.; Barben, J.; Putot, A. Iron in the general population and specificities in older adults: Metabolism, causes and consequences of decrease or overload, and biological assessment. Clin. Interv. Aging 2020, 15, 1927–1938.
  39. Leszek, P.; Sochanowicz, B.; Szperl, M.; Kolsut, P.; Brzóska, K.; Piotrowski, W.; Rywik, T.M.; Danko, B.; Polkowska-Motrenko, H.; Rózański, J.M.; et al. Myocardial iron homeostasis in advanced chronic heart failure patients. Int. J. Cardiol. 2012, 159, 47–52.
  40. Wolf, M.; Rubin, J.; Achebe, M.; Econs, M.J.; Peacock, M.; Imel, E.A.; Thomsen, L.L.; Carpenter, T.O.; Weber, T.; Brandenburg, V.; et al. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials. JAMA 2020, 323, 432–443.
  41. Hirsch, V.G.; Tongers, J.; Bode, J.; Berliner, D.; Widder, J.D.; Escher, F.; Mutsenko, V.; Chung, B.; Rostami, F.; Guba-Quint, A.; et al. Cardiac iron concentration in relation to systemic iron status and disease severity in non-ischaemic heart failure with reduced ejection fraction. Eur. J. Heart Fail. 2020, 22, 2038–2046.
  42. Klip, I.T.; Comin-Colet, J.; Voors, A.A.; Ponikowski, P.; Enjuanes, C.; Banasiak, W.; Lok, D.J.; Rosentryt, P.; Torrens, A.; Polonski, L.; et al. Iron deficiency in chronic heart failure: An international pooled analysis. Am. Heart J. 2013, 165.
  43. Okonko, D.O.; Mandal, A.K.J.; Missouris, C.G.; Poole-Wilson, P.A. Disordered iron homeostasis in chronic heart failure: Prevalence, predictors, and relation to anemia, exercise capacity, and survival. J. Am. Coll. Cardiol. 2011, 58, 1241–1251.
  44. Jankowska, E.A.; Rozentryt, P.; Witkowska, A.; Nowak, J.; Hartmann, O.; Ponikowska, B.; Borodulin-Nadzieja, L.; Von Haehling, S.; Doehner, W.; Banasiak, W.; et al. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J. Card. Fail. 2011, 17, 899–906.
  45. Van Veldhuisen, D.J.; Ponikowski, P.; Van Der Meer, P.; Metra, M.; Böhm, M.; Doletsky, A.; Voors, A.A.; MacDougall, I.C.; Anker, S.D.; Roubert, B.; et al. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients with Chronic Heart Failure and Iron Deficiency. Circulation 2017, 136, 1374–1383.
  46. Paul, B.T.; Manz, D.H.; Torti, F.M.; Torti, S.V. Mitochondria and Iron: Current questions. Expert Rev. Hematol. 2017, 10, 65–79.
  47. Sheeran, F.L.; Pepe, S. Mitochondrial bioenergetics and dysfunction in failing heart. In Mitochondrial Dynamics in Cardiovascular Medicine; Advances in Experimental Medicine and Biology; Springer: New York, NY, USA, 2017; Volume 982, pp. 65–80.
  48. Rensvold, J.W.; Ong, S.E.; Jeevananthan, A.; Carr, S.A.; Mootha, V.K.; Pagliarini, D.J. Complementary RNA and protein profiling identifies iron as a key regulator of mitochondrial biogenesis. Cell Rep. 2013, 3, 237–245.
  49. Baughman, J.M.; Perocchi, F.; Girgis, H.S.; Plovanich, M.; Belcher-Timme, C.A.; Sancak, Y.; Bao, X.R.; Strittmatter, L.; Goldberger, O.; Bogorad, R.L.; et al. Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter. Nature 2011, 476, 341–345.
  50. Walter, P.B.; Knutson, M.D.; Paler-Martinez, A.; Lee, S.; Xu, Y.; Viteri, F.E.; Ames, B.N. Iron deficiency and iron excess damage mitochondria and mitochondrial DNA in rats. Proc. Natl. Acad. Sci. USA 2002, 99, 2264–2269.
  51. Hoes, M.F.; Grote Beverborg, N.; Kijlstra, J.D.; Kuipers, J.; Swinkels, D.W.; Giepmans, B.N.G.; Rodenburg, R.J.; van Veldhuisen, D.J.; de Boer, R.A.; van der Meer, P. Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function. Eur. J. Heart Fail. 2018, 20, 910–919.
  52. Kitamura, N.; Yokoyama, Y.; Taoka, H.; Nagano, U.; Hosoda, S.; Taworntawat, T.; Nakamura, A.; Ogawa, Y.; Tsubota, K.; Watanabe, M. Iron supplementation regulates the progression of high fat diet induced obesity and hepatic steatosis via mitochondrial signaling pathways. Sci. Rep. 2021, 11, 10753.
  53. Finch, C.A.; Gollnick, P.D.; Hlastala, M.P.; Miller, L.R.; Dillmann, E.; Mackler, B. Lactic acidosis as a result of iron deficiency. J. Clin. Invest. 1979, 64, 129–137.
  54. Chung, Y.J.; Swietach, P.; Curtis, M.K.; Ball, V.; Robbins, P.A.; Lakhal-Littleton, S. Iron-Deficiency Anemia Results in Transcriptional and Metabolic Remodeling in the Heart Toward a Glycolytic Phenotype. Front. Cardiovasc. Med. 2021, 7, 361.
  55. Biegus, J.; Zymliński, R.; Sokolski, M.; Jankowska, E.A.; Banasiak, W.; Ponikowski, P. Elevated lactate in acute heart failure patients with intracellular iron deficiency as an identifier of poor outcome. Kardiol. Pol. 2019, 77, 347–354.
  56. Xu, W.; Barrientos, T.; Mao, L.; Rockman, H.A.; Sauve, A.A.; Andrews, N.C. Lethal Cardiomyopathy in Mice Lacking Transferrin Receptor in the Heart. Cell Rep. 2015, 13, 533–545.
  57. Dong, F.; Zhang, X.; Culver, B.; Chew, H.G.; Kelley, R.O.; Ren, J. Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: Involvement of nitric oxide synthase and protein tyrosine nitration. Clin. Sci. 2005, 109, 277–286.
  58. Toblli, J.E.; Cao, G.; Rivas, C.; Kulaksiz, H. Heart and iron deficiency anaemia in rats with renal insufficiency: The role of hepcidin. Nephrology 2008, 13, 636–645.
  59. Dziegala, M.; Kasztura, M.; Kobak, K.; Bania, J.; Banasiak, W.; Ponikowski, P.; Jankowska, E.A. Influence of the availability of iron during hypoxia on the genes associated with apoptotic activity and local iron metabolism in rat H9C2 cardiomyocytes and L6G8C5 skeletal myocytes. Mol. Med. Rep. 2016, 14, 3969–3977.
  60. Kasztura, M.; Dziegała, M.; Kobak, K.; Bania, J.; Mazur, G.; Banasiak, W.; Ponikowski, P.; Jankowska, E.A. Both iron excess and iron depletion impair viability of rat H9C2 cardiomyocytes and L6G8C5 myocytes. Kardiol. Pol. 2017, 75, 267–275.
  61. Dziegala, M.; Kobak, K.; Kasztura, M.; Bania, J.; Josiak, K.; Banasiak, W.; Ponikowski, P.; Jankowska, E. Iron Depletion Affects Genes Encoding Mitochondrial Electron Transport Chain and Genes of Non Oxidative Metabolism, Pyruvate Kinase and Lactate Dehydrogenase, in Primary Human Cardiac Myocytes Cultured upon Mechanical Stretch. Cells 2018, 7, 175.
  62. Kamei, A.; Watanabe, Y.; Ishijima, T.; Uehara, M.; Arai, S.; Kato, H.; Nakai, Y.; Abe, K. Dietary iron-deficient anemia induces a variety of metabolic changes and even apoptosis in rat liver: A DNA microarray study. Physiol. Genomics 2010, 42, 149–156.
  63. Narula, J.; Kolodgie, F.D.; Virmani, R. Apoptosis and cardiomyopathy. Curr. Opin. Cardiol. 2000, 15, 183–188.
  64. Brown, D.A.; Perry, J.B.; Allen, M.E.; Sabbah, H.N.; Stauffer, B.L.; Shaikh, S.R.; Cleland, J.G.F.; Colucci, W.S.; Butler, J.; Voors, A.A.; et al. Expert consensus document: Mitochondrial function as a therapeutic target in heart failure. Nat. Rev. Cardiol. 2017, 14, 238–250.
  65. Kaludercic, N.; Giorgio, V. The dual function of reactive oxygen/nitrogen species in bioenergetics and cell death: The role of ATP synthase. Oxid. Med. Cell. Longev. 2016, 2016, 3869610.
  66. Koskenkorva-Frank, T.S.; Weiss, G.; Koppenol, W.H.; Burckhardt, S. The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: Insights into the potential of various iron therapies to induce oxidative and nitrosative stress. Free Radic. Biol. Med. 2013, 65, 1174–1194.
  67. Inoue, H.; Hanawa, N.; Katsumata, S.I.; Katsumata-Tsuboi, R.; Takahashi, N.; Uehara, M. Iron deficiency induces autophagy and activates Nrf2 signal through modulating p62/SQSTM. Biomed. Res. 2017, 38, 343–350.
  68. Melenovsky, V.; Petrak, J.; Mracek, T.; Benes, J.; Borlaug, B.A.; Nuskova, H.; Pluhacek, T.; Spatenka, J.; Kovalcikova, J.; Drahota, Z.; et al. Myocardial iron content and mitochondrial function in human heart failure: A direct tissue analysis. Eur. J. Heart Fail. 2016, 19, 522–530.
  69. Tsutsui, H.; Kinugawa, S.; Matsushima, S. Mitochondrial oxidative stress and dysfunction in myocardial remodelling. Cardiovasc. Res. 2009, 81, 449–456.
  70. Toblli, J.E.; Cao, G.; Rivas, C.; Giani, J.F.; Dominici, F.P. Intravenous iron sucrose reverses anemia-induced cardiac remodeling, prevents myocardial fibrosis, and improves cardiac function by attenuating oxidative/nitrosative stress and inflammation. Int. J. Cardiol. 2016, 212, 84–91.
  71. Paterek, A.; Kępska, M.; Sochanowicz, B.; Chajduk, E.; Kołodziejczyk, J.; Polkowska-Motrenko, H.; Kruszewski, M.; Leszek, P.; Mackiewicz, U.; Mączewski, M. Beneficial effects of intravenous iron therapy in a rat model of heart failure with preserved systemic iron status but depleted intracellular cardiac stores. Sci. Rep. 2018, 8, 15758.
  72. Inserte, J.; Barrabés, J.A.; Aluja, D.; Otaegui, I.; Bañeras, J.; Castellote, L.; Sánchez, A.; Rodríguez-Palomares, J.F.; Pineda, V.; Miró-Casas, E.; et al. Implications of Iron Deficiency in STEMI Patients and in a Murine Model of Myocardial Infarction. JACC Basic Transl. Sci. 2021, 6, 567–580.
  73. Knutson, M.D.; Walter, P.B.; Ames, B.N.; Viteri, F.E. Both iron deficiency and daily iron supplements increase lipid peroxidation in rats. J. Nutr. 2000, 130, 621–628.
  74. Bhandari, S. Impact of intravenous iron on cardiac and skeletal oxidative stress and cardiac mitochondrial function in experimental uraemia chronic kidney disease. Front. Biosci.—Landmark 2021, 26, 442–464.
  75. Wong, A.-P.; Niedzwiecki, A.; Rath, M. Myocardial energetics and the role of micronutrients in heart failure: A critical review. Am. J. Cardiovasc. Dis. 2016, 6, 81–92.
  76. Rineau, E.; Gaillard, T.; Gueguen, N.; Procaccio, V.; Henrion, D.; Prunier, F.; Lasocki, S. Iron deficiency without anemia is responsible for decreased left ventricular function and reduced mitochondrial complex I activity in a mouse model. Int. J. Cardiol. 2018, 266, 206–212.
  77. Naito, Y.; Tsujino, T.; Matsumoto, M.; Sakoda, T.; Ohyanagi, M.; Masuyama, T. Adaptive response of the heart to long-term anemia induced by iron deficiency. Am. J. Physiol.—Heart Circ. Physiol. 2009, 296, 585–593.
  78. Tanne, Z.; Coleman, R.; Nahir, M.; Shomrat, D.; Finberg, J.P.M.; Youdim, M.B.H. Ultrastructural and cytochemical changes in the heart of iron-deficient rats. Biochem. Pharmacol. 1994, 47, 1759–1766.
  79. Kobak, K.A.; Radwańska, M.; Dzięgała, M.; Kasztura, M.; Josiak, K.; Banasiak, W.; Ponikowski, P.; Jankowska, E.A. Structural and functional abnormalities in iron-depleted heart. Heart Fail. Rev. 2019, 24, 269–277.
  80. Chung, Y.J.; Luo, A.; Park, K.C.; Loonat, A.A.; Lakhal-Littleton, S.; Robbins, P.A.; Swietach, P. Iron-deficiency anemia reduces cardiac contraction by downregulating RyR2 channels and suppressing SERCA pump activity. JCI Insight 2019, 4, e125618.
  81. Haddad, S.; Wang, Y.; Galy, B.; Korf-Klingebiel, M.; Hirsch, V.; Baru, A.M.; Rostami, F.; Reboll, M.R.; Heineke, J.; Flögel, U.; et al. Iron-regulatory proteins secure iron availability in cardiomyocytes to prevent heart failure. Eur. Heart J. 2016, 38, ehw333.
  82. Martens, P.; Verbrugge, F.H.; Nijst, P.; Dupont, M.; Mullens, W. Limited contractile reserve contributes to poor peak exercise capacity in iron-deficient heart failure. Eur. J. Heart Fail. 2018, 20, 806–808.
  83. Núñez, J.; Miñana, G.; Cardells, I.; Palau, P.; Llàcer, P.; Fácila, L.; Almenar, L.; López-Lereu, M.P.; Monmeneu, J.V.; Amiguet, M.; et al. Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial-IRON Trial. J. Am. Heart Assoc. 2020, 9, e014254.
  84. Grote Beverborg, N.; Van Der Wal, H.H.; Klip, I.T.; Anker, S.D.; Cleland, J.; Dickstein, K.; Van Veldhuisen, D.J.; Voors, A.A.; Van Der Meer, P. Differences in Clinical Profile and Outcomes of Low Iron Storage vs. Defective Iron Utilization in Patients with Heart Failure: Results from the DEFINE-HF and BIOSTAT-CHF Studies. JAMA Cardiol. 2019, 4, 696–701.
  85. Petrak, J.; Havlenova, T.; Krijt, M.; Behounek, M.; Franekova, J.; Cervenka, L.; Pluhacek, T.; Vyoral, D.; Melenovsky, V. Myocardial iron homeostasis and hepcidin expression in a rat model of heart failure at different levels of dietary iron intake. Biochim. Biophys. Acta—Gen. Subj. 2019, 1863, 703–713.
  86. Santas, E.; Miñana, G.; Cardells, I.; Palau, P.; Llàcer, P.; Fácila, L.; Almenar, L.; López-Lereu, M.P.; Monmeneu, J.V.; Sanchis, J.; et al. Short-term changes in left and right systolic function following ferric carboxymaltose: A substudy of the Myocardial-IRON trial. ESC Heart Fail. 2020, 7, 4222–4230.
  87. Toblli, J.E.; Di Gennaro, F.; Rivas, C. Changes in echocardiographic parameters in iron deficiency patients with heart failure and chronic kidney disease treated with intravenous iron. Heart Lung Circ. 2015, 24, 686–695.
  88. Usmanov, R.I.; Zueva, E.B.; Silverberg, D.S.; Shaked, M. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency. J. Nephrol. 2008, 21, 2236–2242.
  89. Gaber, R.; Kotb, N.A.; Ghazy, M.; Nagy, H.M.; Salama, M.; Elhendy, A. Tissue doppler and strain rate imaging detect improvement of myocardial function in iron deficient patients with congestive heart failure after Iron replacement therapy. Echocardiography 2012, 29, 13–18.
  90. Núñez, J.; Monmeneu, J.V.; Mollar, A.; Núñez, E.; Bodí, V.; Miñana, G.; García-Blas, S.; Santas, E.; Agüero, J.; Chorro, F.J.; et al. Left ventricular ejection fraction recovery in patients with heart failure treated with intravenous iron: A pilot study. ESC Heart Fail. 2016, 3, 293–298.
  91. Martens, P.; Verbrugge, F.; Nijst, P.; Dupont, M.; Tang, W.H.W.; Mullens, W. Impact of Iron Deficiency on Response to and Remodeling After Cardiac Resynchronization Therapy. Am. J. Cardiol. 2017, 119, 65–70.
  92. Lacour, P.; Dang, P.L.; Morris, D.A.; Parwani, A.S.; Doehner, W.; Schuessler, F.; Hohendanner, F.; Heinzel, F.R.; Stroux, A.; Tschoepe, C.; et al. The effect of iron deficiency on cardiac resynchronization therapy: Results from the RIDE-CRT Study. ESC Heart Fail. 2020, 7, 1072–1084.
  93. Nijst, P.; Martens, P.; Mullens, W. Heart Failure with Myocardial Recovery—The Patient Whose Heart Failure Has Improved: What Next? Prog. Cardiovasc. Dis. 2017, 60, 226–236.
  94. Chang, H.C.; Shapiro, J.S.; Ardehali, H. Getting to the “heart” of Cardiac Disease by Decreasing Mitochondrial Iron. Circ. Res. 2016, 119, 1164–1166.
  95. Lupu, M.; Tudor, D.V.; Filip, G.A. Influence of mitochondrial and systemic iron levels in heart failure pathology. Heart Fail. Rev. 2019, 24, 647–659.
  96. Sawicki, K.T.; Shang, M.; Wu, R.; Chang, H.C.; Khechaduri, A.; Sato, T.; Kamide, C.; Liu, T.; Naga Prasad, S.V.; Ardehali, H. Increased Heme Levels in the Heart Lead to Exacerbated Ischemic Injury. J. Am. Heart Assoc. 2015, 4, e002272.
  97. Khechaduri, A.; Bayeva, M.; Chang, H.C.; Ardehali, H. Heme levels are increased in human failing hearts. J. Am. Coll. Cardiol. 2013, 61, 1884–1893.
  98. Mancini, D.M.; Walter, G.; Reichek, N.; Lenkinski, R.; McCully, K.K.; Mullen, J.L.; Wilson, J.R. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation 1992, 85, 1364–1373.
  99. Stugiewicz, M.; Tkaczyszyn, M.; Kasztura, M.; Banasiak, W.; Ponikowski, P.; Jankowska, E.A. The influence of iron deficiency on the functioning of skeletal muscles: Experimental evidence and clinical implications. Eur. J. Heart Fail. 2016, 18, 762–773.
  100. Haas, J.D.; Brownlie IV, T. Iron deficiency and reduced work capacity: A critical review of the research to determine a causal relationship. J. Nutr. 2001, 131, 676S–690S.
  101. Finch, C.A.; Miller, L.R.; Inamdar, A.R.; Person, R.; Seiler, K.; Mackler, B. Iron deficiency in the rat. Physiological and biochemical studies of muscle dysfunction. J. Clin. Invest. 1976, 58, 447–453.
  102. Rineau, E.; Gueguen, N.; Procaccio, V.; Geneviève, F.; Reynier, P.; Henrion, D.; Lasocki, S. Iron deficiency without anemia decreases physical endurance and mitochondrial complex i activity of oxidative skeletal muscle in the mouse. Nutrients 2021, 13, 1056.
  103. Burden, R.J.; Morton, K.; Richards, T.; Whyte, G.P.; Pedlar, C.R. Is iron treatment beneficial in, irondeficient but nonanaemic (IDNA) endurance athletes? A systematic review and metaanalysis. Br. J. Sports Med. 2015, 49, 1389–1397.
  104. Barrientos, T.; Laothamatas, I.; Koves, T.R.; Soderblom, E.J.; Bryan, M.; Moseley, M.A.; Muoio, D.M.; Andrews, N.C. Metabolic Catastrophe in Mice Lacking Transferrin Receptor in Muscle. EBioMedicine 2015, 2, 1705–1717.
  105. Ponikowski, P.; Van Veldhuisen, D.J.; Comin-Colet, J.; Ertl, G.; Komajda, M.; Mareev, V.; McDonagh, T.; Parkhomenko, A.; Tavazzi, L.; Levesque, V.; et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur. Heart J. 2015, 36, 657–668.
  106. Charles-Edwards, G.; Amaral, N.; Sleigh, A.; Ayis, S.; Catibog, N.; McDonagh, T.; Monaghan, M.; Amin-Youssef, G.; Kemp, G.J.; Shah, A.M.; et al. Effect of Iron Isomaltoside on Skeletal Muscle Energetics in Patients with Chronic Heart Failure and Iron Deficiency: FERRIC-HF II Randomized Mechanistic Trial. Circulation 2019, 139, 2386–2398.
  107. Forbes, J.M.; Thorburn, D.R. Mitochondrial dysfunction in diabetic kidney disease. Nat. Rev. Nephrol. 2018, 14, 291–312.
  108. Thévenod, F.; Lee, W.K.; Garrick, M.D. Iron and Cadmium Entry Into Renal Mitochondria: Physiological and Toxicological Implications. Front. Cell Dev. Biol. 2020, 8, 848.
  109. Van Swelm, R.P.L.; Wetzels, J.F.M.; Swinkels, D.W. The multifaceted role of iron in renal health and disease. Nat. Rev. Nephrol. 2020, 16, 77–98.
  110. Del Greco, F.M.; Foco, L.; Pichler, I.; Eller, P.; Eller, K.; Benyamin, B.; Whitfield, J.B.; Pramstaller, P.P.; Thompson, J.R.; Pattaro, C.; et al. Serum iron level and kidney function: A Mendelian randomization study. Nephrol. Dial. Transplant. 2017, 32, 273–278.
  111. El-Shimi, M.S.; El-Farrash, R.A.; Ismail, E.A.; El-Safty, A.; Nada, A.S.; El-Gamel, O.A.; Salem, Y.M.; Shoukry, S.M. Renal functional and structural integrity in infants with iron deficiency anemia: Relation to oxidative stress and response to iron therapy. Pediatr. Nephrol. 2015, 30, 1835–1842.
  112. Toblli, J.E.; Lombraña, A.; Duarte, P.; Di Gennaro, F. Intravenous Iron Reduces NT-Pro-Brain Natriuretic Peptide in Anemic Patients With Chronic Heart Failure and Renal Insufficiency. J. Am. Coll. Cardiol. 2007, 50, 1657–1665.
  113. Ponikowski, P.; Filippatos, G.; Colet, J.C.; Willenheimer, R.; Dickstein, K.; Lüscher, T.; Gaudesius, G.; Von Eisenhart Rothe, B.; Mori, C.; Greenlaw, N.; et al. The impact of intravenous ferric carboxymaltose on renal function: An analysis of the FAIR-HF study. Eur. J. Heart Fail. 2015, 17, 329–339.
  114. Stöhr, R.; Sandstede, L.; Heine, G.H.; Marx, N.; Brandenburg, V. High-Dose Ferric Carboxymaltose in Patients With HFrEF Induces Significant Hypophosphatemia. J. Am. Coll. Cardiol. 2018, 71, 2270–2271.
  115. Courbon, G.; Martinez-Calle, M.; David, V. Simultaneous management of disordered phosphate and iron homeostasis to correct fibroblast growth factor 23 and associated outcomes in chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 2020, 29, 359–366.
  116. Stöhr, R.; Schuh, A.; Heine, G.H.; Brandenburg, V. FGF23 in cardiovascular disease: Innocent bystander or active mediator? Front. Endocrinol. 2018, 9, 351.
  117. Lanser, L.; Fuchs, D.; Kurz, K.; Weiss, G. Physiology and inflammation driven pathophysiology of iron homeostasis—mechanistic insights into anemia of inflammation and its treatment. Nutrients 2021, 13, 3732.
  118. Van der Wal, H.H.; Beverborg, N.G.; ter Maaten, J.M.; Vinke, J.S.J.; de Borst, M.H.; van Veldhuisen, D.J.; Voors, A.A.; van der Meer, P. Fibroblast growth factor 23 mediates the association between iron deficiency and mortality in worsening heart failure. Eur. J. Heart Fail. 2020, 22, 903–906.
  119. Mu, Q.; Chen, L.; Gao, X.; Shen, S.; Sheng, W.; Min, J.; Wang, F. The role of iron homeostasis in remodeling immune function and regulating inflammatory disease. Sci. Bull. 2021, 66, 1806–1816.
  120. Cherayil, B.J. Iron and immunity: Immunological consequences of iron deficiency and overload. Arch. Immunol. Ther. Exp. 2010, 58, 407–415.
  121. Weiss, G. Iron and Immunity: A Double-Edged Sword. Eur. J. Clin. Investig. 2002, 32, 70–78.
  122. Ward, R.J.; Crichton, R.R.; Taylor, D.L.; Della Corte, L.; Srai, S.K.; Dexter, D.T. Iron and the immune system. J. Neural Transm. 2011, 118, 315–328.
  123. Cronin, S.J.F.; Woolf, C.J.; Weiss, G.; Penninger, J.M. The Role of Iron Regulation in Immunometabolism and Immune-Related Disease. Front. Mol. Biosci. 2019, 6, 116.
  124. Howden, A.J.M.; Hukelmann, J.L.; Brenes, A.; Spinelli, L.; Sinclair, L.V.; Lamond, A.I.; Cantrell, D.A. Quantitative analysis of T cell proteomes and environmental sensors during T cell differentiation. Nat. Immunol. 2019, 20, 1542–1554.
  125. Omara, F.O.; Blakley, B.R. The effects of iron deficiency and iron overload on cell-mediated immunity in the mouse. Br. J. Nutr. 1994, 72, 899–909.
  126. Spear, A.T.; Sherman, A.R. Iron deficiency alters DMBA-induced tumor burden and natural killer cell cytotoxicity in rats. J. Nutr. 1992, 122, 46–55.
  127. Ganz, T.; Nemeth, E. Iron homeostasis in host defence and inflammation. Nat. Rev. Immunol. 2015, 15, 500–510.
  128. Pagani, A.; Nai, A.; Corna, G.; Bosurgi, L.; Rovere-Querini, P.; Camaschella, C.; Silvestri, L. Low hepcidin accounts for the proinflammatory status associated with iron deficiency. Blood 2011, 118, 736–746.
  129. Shayganfard, M. Are Essential Trace Elements Effective in Modulation of Mental Disorders? Update and Perspectives. Biol. Trace Elem. Res. 2021, 1–28.
  130. Ferreira, A.; Neves, P.; Gozzelino, R. Multilevel impacts of iron in the brain: The cross talk between neurophysiological mechanisms, cognition, and social behavior. Pharmaceuticals 2019, 12, 126.
  131. Todorich, B.; Pasquini, J.M.; Garcia, C.I.; Paez, P.M.; Connor, J.R. Oligodendrocytes and myelination: The role of iron. Glia 2009, 57, 467–478.
  132. Kim, J.; Wessling-Resnick, M. Iron and mechanisms of emotional behavior. J. Nutr. Biochem. 2014, 25, 1101–1107.
  133. Belmaker, R.H.; Agam, G. Major Depressive Disorder. N. Engl. J. Med. 2008, 358, 55–68.
  134. Di Palo, K.E. Psychological Disorders in Heart Failure. Heart Fail. Clin. 2020, 16, 131–138.
  135. Barandiarán Aizpurua, A.; Sanders-van Wijk, S.; Brunner-La Rocca, H.P.; Henkens, M.T.H.M.; Weerts, J.; Spanjers, M.H.A.; Knackstedt, C.; van Empel, V.P.M. Iron deficiency impacts prognosis but less exercise capacity in heart failure with preserved ejection fraction. ESC Heart Fail. 2021, 8, 1304–1313.
  136. Huang, K.W.; Bilgrami, N.L.; Hare, D.L. Iron Deficiency in Heart Failure Patients and Benefits of Iron Replacement on Clinical Outcomes Including Comorbid Depression. Heart Lung Circ. 2021.
  137. Vargas-Uricoechea, H.; Bonelo-Perdomo, A. Thyroid Dysfunction and Heart Failure: Mechanisms and Associations. Curr. Heart Fail. Rep. 2017, 14, 48–58.
  138. Razvi, S.; Jabbar, A.; Pingitore, A.; Danzi, S.; Biondi, B.; Klein, I.; Peeters, R.; Zaman, A.; Iervasi, G. Thyroid Hormones and Cardiovascular Function and Diseases. J. Am. Coll. Cardiol. 2018, 71, 1781–1796.
  139. Maldonado-Araque, C.; Valdés, S.; Lago-Sampedro, A.; Lillo-Muñoz, J.A.; Garcia-Fuentes, E.; Perez-Valero, V.; Gutierrez-Repiso, C.; Goday, A.; Urrutia, I.; Peláez, L.; et al. Iron deficiency is associated with Hypothyroxinemia and Hypotriiodothyroninemia in the Spanish general adult population: study. Sci. Rep. 2018, 8, 6571.
  140. Beard, J.; Tobin, B.; Green, W. Evidence for thyroid hormone deficiency in iron-deficient anemic rats. J. Nutr. 1989, 119, 772–778.
  141. Crielaard, B.J.; Lammers, T.; Rivella, S. Targeting iron metabolism in drug discovery and delivery. Nat. Rev. Drug Discov. 2017, 16, 400–423.
  142. Anand, I.S.; Gupta, P. Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies. Circulation 2018, 138, 80–98.
  143. Sheetz, M.; Barrington, P.; Callies, S.; Berg, P.H.; McColm, J.; Marbury, T.; Decker, B.; Dyas, G.L.; Truhlar, S.M.E.; Benschop, R.; et al. Targeting the hepcidin–ferroportin pathway in anaemia of chronic kidney disease. Br. J. Clin. Pharmacol. 2019, 85, 935–948.
  144. Pergola, P.E.; Devalaraja, M.; Fishbane, S.; Chonchol, M.; Mathur, V.S.; Smith, M.T.; Lo, L.; Herzog, K.; Kakkar, R.; Davidson, M.H. Ziltivekimab for treatment of anemia of inflammation in patients on hemodialysis: Results from a phase 1/2 multicenter, randomized, double-blind, placebo-controlled trial. J. Am. Soc. Nephrol. 2021, 32, 211–222.
  145. Alnuwaysir, R.I.S.; Grote Beverborg, N.; Hoes, M.F.; Markousis-Mavrogenis, G.; Gomez, K.A.; Wal, H.H.; Cleland, J.G.F.; Dickstein, K.; Lang, C.C.; Ng, L.L.; et al. Additional Burden of Iron Deficiency in Heart Failure Patients beyond the Cardio-Renal-Anaemia Syndrome: Findings from the BIOSTAT-CHF Study. Eur. J. Heart Fail. 2021.
  146. Crugliano, G.; Serra, R.; Ielapi, N.; Battaglia, Y.; Coppolino, G.; Bolignano, D.; Bracale, U.M.; Pisani, A.; Faga, T.; Michael, A.; et al. Hypoxia-inducible factor stabilizers in end stage kidney disease: “Can the promise be kept”? Int. J. Mol. Sci. 2021, 22, 12590.
  147. Liu, J.; Zhang, A.; Hayden, J.C.; Bhagavathula, A.S.; Alshehhi, F.; Rinaldi, G.; Kontogiannis, V.; Rahmani, J. Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and meta-analysis. Pharmacol. Res. 2020, 155, 104747.
  148. Chen, H.; Cheng, Q.; Wang, J.; Zhao, X.; Zhu, S. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients. J. Clin. Pharm. Ther. 2021, 46, 999–1009.
  149. Provenzano, R.; Besarab, A.; Wright, S.; Dua, S.; Zeig, S.; Nguyen, P.; Poole, L.; Saikali, K.G.; Saha, G.; Hemmerich, S.; et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: A phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am. J. Kidney Dis. 2016, 67, 912–924.
  150. Haase, V.H. HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism. Hemodial. Int. 2017, 21, S110–S124.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Cardiac & Cardiovascular Systems
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Niels Grote Beverborg
,
,
Peter Van Der Meer
View Times: 769
Revisions: 3 times (View History)
Update Date: 11 Apr 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback